Cost-effectiveness of initiating extrafine-or standard size-particle inhaled corticosteroid for asthma in two health-care systems: A retrospective matched cohort study

npj Primary Care Respiratory Medicine

Volumn 24, Issue , 2014, Pages

  Martin, Richard J ^a   Price, David ^b,c   Roche, Nicolas ^d   Israel, Elliot ^e   Van Aalderen, Willem M C ^f   Grigg, Jonathan ^g   Postma, Dirkje S ^h   Guilbert, Theresa W ⁱ   Hillyer, Elizabeth V ^c   Burden, Anne ^c   Von Ziegenweidt, Julie ^c   Colice, Gene ^j  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Research in Real Life Ltd   (United Kingdom)

^d Cochin Hospital Group APHP University of Paris Descartes ^*  (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; FLUTICASONE; CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HEALTH CARE DELIVERY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PARTICLE SIZE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84936928616     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2014.81     Document Type: Article

References (36)

1. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333, 294 patients. J R Soc Med 2010; 103: 98-106.
2. Zahran HS, Bailey C, Garbe P. Vital signs: asthma prevalence, disease characteristics, and self-management education-United States, 2001-2009. MMWR 2011; 60: 547-552.
3. Meltzer EO, Blaiss MS, Nathan RA, Doherty DE, Murphy KR, Stoloff SW. Asthma burden in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012; 33: 36-46.
4. Asthma UK. Asthma facts and FAQs, updated 2013. Available from http://www. asthma.org.uk/asthma-facts-and-statistics (accessed 14 January 2014).
5. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011; 127: 145-152.
6. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010; 17: 74-80.
7. Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013; 160: 93-101.
8. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, 2007. Available from http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 14 January 2014).
9. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma, May 2008, revised Jan 2012. Available from http://www.sign.ac.uk/guidelines/fulltext/101/index.html (accessed 14 January 2014).
10. Jarvinen TL, Sievanen H, Kannus P, Jokihaara J, Khan KM. The true cost of pharmacological disease prevention. BMJ 2011; 342: d2175.
11. Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010; 126: 511-518, e511-510.
12. Colice G, Martin RJ, Israel E, Roche N, Barnes N, Burden A et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013; 132: 45-54, e10.
13. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009; 124: S88-S93.
14. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chloro-fluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122: 510-516.
15. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(Suppl B): S3-S9.
16. Clinical Practice Research Datalink. Available from http://www.cprd.com/home/(accessed 14 January 2014.
17. OptumInsight Research Database. Available from http://www.optuminsight.com/life-sciences/solutions/real-world-evidence/data-assets/retrospective-database/overview/(accessed 14 January 2014).
18. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
19. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012; 129: S49-S64.
20. Schatz M, Zeiger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117: 995-1000.
21. Personal Social Services Research Unit. Unit costs of health and social care 2007. Available from http://www.pssru.ac.uk/project-pages/unit-costs/2007/index.php (accessed 14 January 2014).
22. British National Formulary. v. 54 ed. British Medical Association and the Royal Pharmaceutical Society of Great Britain. London, UK, 2007.
23. Department of Health. NHS reference costs 2007-2008. Available from http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHScostingmanual/index.htm (accessed 14 January 2014).
24. Bureau of Labor Statistics. 2010, Consumer Price Index. Available from http://www.bls.gov/schedule/archives/cpi-nr.htm#2010 (accessed 14 January 2014).
25. Research in Real Life: Standard Operating Procedures. Available from http://www. optimumpatientcare.org/Docs/SOP%20Observational%20Database%20Studies.pdf (accessed 14 January 2014).
26. Thompson SG, Nixon RM, Grieve R. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. J Health Econ 2006; 25: 1015-1028.
27. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
28. Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J et al. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics 2010; 28: 585-595.
29. Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008; 12: iii-iv, 1-360.
30. Bahadori K, Quon BS, Doyle-Waters MM, Marra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy 2010; 3: 33-42.
31. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics 2007; 25: 577-590.
32. Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002; 20: 653-664.
33. Lage MJ, Gross GN, Brewster C, Spalitto A. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate. Adv Ther 2009; 26: 762-775.
34. Lasserson TJ, Cates CK, Jones AB, Steele EH, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; (2): CD005309.
35. Shenolikar R, Song X, Anderson JA, Chu BC, Cantrell CR. Costs of asthma among US working adults. Am J Manag Care 2011; 17: 409-416.
36. Lipworth B. Targeting the small airways asthma phenotype: if we can reach it, should we treat it? Ann Allergy Asthma Immunol 2013; 110: 233-239.